AI trained to spot dead jawbone on routine dental X-Rays
NCT ID NCT07809048
First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time
Summary
Researchers at Izmir Katip Celebi University are testing a deep learning model called UNet to automatically outline bone sequestra, pieces of dead jawbone, on panoramic dental X-rays. The study uses 120 anonymized X-rays with 134 marked lesions from patients who had radiotherapy, bisphosphonate or antiangiogenic drug use, trauma, or osteomyelitis. The goal is to see whether the model can match expert markings and reduce the time and disagreement involved in reading these images.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a UNet-based deep learning model for segmenting bone sequestra on panoramic dental X-rays
- What this could lead to
- If it works, dentists and surgeons could get faster, more consistent outlines of dead jawbone on routine panoramic X-rays, which may help them plan treatment for osteomyelitis, osteoradionecrosis, and medication-related osteonecrosis of the jaw.
- What could go wrong
- This is a small, single-center study using 120 archived X-rays, so the model may not perform as well on images from other clinics or with different equipment. It is a diagnostic aid, not a treatment, and it still needs validation in real clinical settings before it could be trusted in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
120 people
The number who actually took part.
- Started
-
Mar 2024
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients will be selected among the patients with osteomyelitis with sequestrum
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient with exposed bone over 8 weeks with a history of bisphosphonates or antiangiogenic drugs, * Patient with a history of previous radiotherapy, * Patients with necrotic exposed bone with or without a history of trauma * Patients with osteomyelitis. Exclusion Criteria: * Patients with no clear vision of the borders of the sequestra, * Panoramic images with artifacts in and around the lesion.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Medication-related osteonecrosis of the jaw are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Izmir Katip Celebi University
Izmir, Çiğli, 35640, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a model predict the right dose of rifampicin for bone infections?
- Can telemedicine bring IV antibiotics home?
- Healing heel bone infections: could an antibiotic bone graft be the key?
- Radiation's hidden toll: study tracks tooth loss in cancer survivors
- Blood-Derived clots could protect jaw bone after tooth removal
- New study uses 3D scans to track jaw bone damage from common osteoporosis drugs